Category: biotech

.AstraZeneca execs say they are “certainly not worried” that the failing of tozorakimab in a stage 2 persistent oppositional pulmonary ailment (COPD) trial are going

.Ascendis Pharma has emerged as a potential danger to BioMarin’s Voxzogo, mentioning stage 3 growth ailment data that exceeded analyst desires and install the biotech

.After connecting to greater than 200 providers to companion a Tourette syndrome treatment that presented the capability to trump standard of care in 2014, Asarina

.Arsenal Biosciences is going on up. The cell therapy firm has actually added on $325 million in ammo along with big-name endorsers like Regeneron joining

.Arrowhead Pharmaceuticals has actually shown its give in front of a possible showdown with Ionis, publishing stage 3 records on an unusual metabolic ailment procedure

.Along with brand new records out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of experts figures the business could give Merck’s Welireg a compete

.On the heels of a $3 billion fund from Bain Funds Life Sciences, Arch Project Allies is verifying it can go toe-to-toe along with the

.Italian biotech Aptadir Therapies has actually introduced with the pledge that its pipe of preclinical RNA inhibitors could fracture unbending cancers cells.The Milan-based firm was

.Italy’s Angelini Pharma has signed a $360 million biobucks deal centered on a stage 1-stage brain health and wellness medicine from South Korea’s Cureverse.The property,

.Avidity Biosciences pleased clients along with phase 1/2 information in Duchenne muscle dystrophy (DMD) Friday, extending its own winning streak in the facility. But more